Literature DB >> 33612156

The Evaluation of Orphan Drugs by the German Joint Federal Committee-An Eight-Year Review.

Sandra Schulz1, Anna Marie Passon, Matthias Perleth, Michael Kulig, Nina Paschke, Katja Matthias.   

Abstract

Mesh：

Year:  2020        PMID： 33612156      PMCID： PMC8025936          DOI： 10.3238/arztebl.2020.0868

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  3 in total

1.  Reforming the Orphan Drug Act for the 21st Century.

Authors:  Ameet Sarpatwari; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2019-07-11       Impact factor: 91.245

2.  [Studies in Rare Diseases: A Descriptive Analysis of Completed Orphan Drug Benefit Assessments at the Federal Joint Committee].

Authors:  Sandra Schulz; Anna Passon; Michael Kulig; Matthias Perleth; Katja Matthias
Journal:  Gesundheitswesen       Date:  2017-05-18

3.  Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.

Authors:  Kerstin Noëlle Vokinger; Aaron S Kesselheim
Journal:  BMJ Open       Date:  2019-10-10       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.